Ab#0848 @RheumNow #ACR23 Biomarkers to Differentiate Flare from Bacterial Ifn in SLE CD14 and CD64 modest increase in infections v flare, better than IL-6 and MRP8/14 One marker not enough to differentiate, but in combo w/ complements, procal, dsDNA improves composite scores https://t.co/MeMYbkMTQH

The belimumab-rituximab combination has utility in SLE, but it comes at an incremental safety cost. May well be worth it in many of our patients, but very understandable that the @US_FDA label gets further clarification #ACR23 @US_FDA session @RheumNow https://t.co/RwF2wbsrQk

#ACR23 Abstr#0782 Triple therapy in #lupus nephritis. Propensity match data AURORA vs ALMS showed pts treated with voclosporin+MMF+low dose GC vs MMF+High dose GC achieved earlier reduction in UPCR & fewer AEs. Cdnt control for everything e.g. HCQ but assuring @RheumNow #ACRBest https://t.co/dmriAyQPr0

What do you think of CAR T Rx in severe #SLE? @RheumNow @ACRheum #ACR23

Ab#0596 #ACR23 @RheumNow R Furie on Decravacitinib in SLE 48wk double-blind trial. PBO v DEU 3mgBID, 6 mgBID,12 mg qd Higher response, faster time to SRI(4), BICLA and dual response v PBO. More likely to sustain response from w32-48. https://t.co/M34d3nQmwv

LEGACY Cohort - Rx monitoring AZA/Tacro in SLE pregnancy Ab#0586 #ACR23 @RheumNow 70 pregnancie. 33% prescribed AZA, 9% TAC AZA - 91% subtherapeutic or non-adherent More likely in non-Caucasian, on steroids, longer SLE duration, prior lupus nephritis TAC - 3/6 therapeutic levels

Targeted OX40L (co-stimulatory APC protein w/ possible polymorphisms in SLE) study by Womba et al, found OX40L targeted CAR-Tregs had superior in vitro suppression of activated T cells & dendritic cells relative to Control-Tregs. #ACR23 Abs 0799 https://t.co/GgCGGIvhHF @rheumnow https://t.co/GZMEUCTooh

Should the cost of #CAR-T stop us from considering in severe refractory #lupus? So far update of German group show remission - drug free and great safety. But hold on..we need RCTs with an active control and longer f/u, but I am impressed! #ACR23 #ACRbest @ACRheum @RheumNow #784 https://t.co/mRMWLCbpCY

#ACR23 tidbits from Sunday @ACRheum @RheumNow 1 Less steroids better w other #Rx in #GCA, #PMR, #SLE #nephritis, #nonrenal #lupus BUT NOT in Severe GCA 2 Trend for combined immune modulators in #lupus GN or w a #CNI 3 #HCQ is better than sliced bread in #SLE aim for drug level

Differences in #glucocorticoid dosing. In #lupus #nephritis less steroids are the same as high dose steroids. Placebo arms of pooled data from #LN #RCTs. Less is equal! #ACRbest #ACR2023 ⁦@RheumNow⁩ ⁦@ACRheum⁩ abst0781 High dose steroids tended to have lower MMF doses https://t.co/XwTlsy4xKE